Literature DB >> 27155186

CYP7A1, BAAT and UGT1A1 polymorphisms and susceptibility to anti-tuberculosis drug-induced hepatotoxicity.

R Chen1, J Wang1, S-W Tang2, Y Zhang3, X-Z Lv4, S-S Wu1, Z-R Yang1, Y-Y Xia5, D-F Chen1, S-Y Zhan1.   

Abstract

SETTING: Evidence indicates that the polymorphisms in genes involved in bile acid metabolism may play an important role in the development of anti-tuberculosis drug-induced hepatotoxicity (ATDH) in tuberculosis (TB) patients treated with anti-tuberculosis drugs.
OBJECTIVE: To investigate the association between genetic variants of CYP7A1, BAAT and UGT1A1 and the risk of ATDH in a Chinese cohort.
DESIGN: In this nested case-control study, 89 TB patients with ATDH and 356 matched ATDH-free TB patients constituted cases and controls, respectively. Genetic polymorphisms of CYP7A1, BAAT and UGT1A1 were determined using the TaqMan single-nucleotide polymorphism genotyping assay. Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated using a conditional logistic regression model.
RESULTS: Significant differences were found in genotype distributions of rs1457043 in CYP7A1 between patients with and those without ATDH (P = 0.014). Genotype and haplotype analysis showed that patients carrying an AG genotype of rs1457043 and G-C or G-A haplotypes of rs1457043-rs8192870 in CYP7A1 were at a higher risk of ATDH than those with GG genotype and A-C haplotype, with ORs of respectively 2.05 (95%CI 1.18-3.15) and 2.40 (95%CI 1.62-3.57).
CONCLUSION: Genetic polymorphisms of CYP7A1 may be associated with susceptibility to ATDH in the Chinese population.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27155186     DOI: 10.5588/ijtld.15.0450

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  4 in total

1.  Interactions Between Regulatory Variants in CYP7A1 (Cholesterol 7α-Hydroxylase) Promoter and Enhancer Regions Regulate CYP7A1 Expression.

Authors:  Danxin Wang; Katherine Hartmann; Michal Seweryn; Wolfgang Sadee
Journal:  Circ Genom Precis Med       Date:  2018-10

2.  Genetic Polymorphisms of SLCO1B1, CYP2E1 and UGT1A1 and Susceptibility to Anti-Tuberculosis Drug-Induced Hepatotoxicity: A Chinese Population-Based Prospective Case-Control Study.

Authors:  Qin Sun; Hai-Peng Liu; Rui-Juan Zheng; Peng Wang; Zhi-Bin Liu; Wei Sha; He-Ping Xiao
Journal:  Clin Drug Investig       Date:  2017-12       Impact factor: 2.859

3.  Genetic Variations Associated with Anti-Tuberculosis Drug-Induced Liver Injury.

Authors:  Yifan Bao; Xiaochao Ma; Theodore P Rasmussen; Xiao-Bo Zhong
Journal:  Curr Pharmacol Rep       Date:  2018-03-15

4.  Home-based Anti-Tuberculosis Treatment Adverse Reactions (HATTAR) study: a protocol for a prospective observational study.

Authors:  Miaomiao Yang; Hongqiu Pan; Lihuan Lu; Xiaomin He; Hongbo Chen; Bilin Tao; Wenpei Liu; Honggang Yi; Shaowen Tang
Journal:  BMJ Open       Date:  2019-03-30       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.